EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”

Imtiaz A Samjoo

Drugs in R&D · 2026-03 · 26 (1) · 35-37

DOI: 10.1007/s40268-026-00536-x ↗

Kurz gefasst

Leserbrief in der Zeitschrift Drugs in R&D, online erschienen am 28.03.2026. Verfasst von Imtiaz A Samjoo. Beteiligte Einrichtung: EVERSANA, 113-3228 South Service Road, Burlington, ON, L7N 3H8, Canada. Imtiaz.Samjoo@Eversana.com. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • EVERSANA, 113-3228 South Service Road, Burlington, ON, L7N 3H8, Canada. Imtiaz.Samjoo@Eversana.com.

Zitieren

APA

Samjoo, I. A. (2026). Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”. Drugs in R&D, 26(1), 35-37. https://doi.org/10.1007/s40268-026-00536-x

Vancouver

Samjoo IA. Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”. Drugs in R&D. 2026;26(1):35-37. doi:10.1007/s40268-026-00536-x

BibTeX
@article{Samjoo2026,
  author = {Samjoo, Imtiaz A},
  title = {Response to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”},
  journal = {Drugs in R&D},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {35--37},
  doi = {10.1007/s40268-026-00536-x}
}
Kostenlos starten →